Stocks and Investing
Stocks and Investing
Wed, February 28, 2024
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
[ Wed, Feb 28th 2024
] - WOPRAI
Serge Belanger Maintained (ARQT) at Strong Buy with Increased Target to $16 on, Feb 28th, 2024
Serge Belanger of Needham, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Strong Buy with Increased Target from $8 to $16 on, Feb 28th, 2024.
Serge has made no other calls on ARQT in the last 4 months.
There are 2 other peers that have a rating on ARQT. Out of the 2 peers that are also analyzing ARQT, 1 agrees with Serge's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Sean Kim of "JonesTrading" Downgraded from Strong Buy to Hold on, Wednesday, November 8th, 2023
This is the rating of the analyst that currently disagrees with Serge
- Nigel Dally of "Morgan Stanley" Maintained at Buy with Decreased Target to $10 on, Monday, November 13th, 2023
Contributing Sources